DuPont is investing more than $30 million in the Tyvek® Medical Packaging Transition Project (MPTP) to ensure continuity and flexibility of future supply.
Oliver™ has been involved with DuPont’s MPTP since its initiation in June 2011 when DuPont announced their intention to transition the manufacture of Tyvek® 1073B and Tyvek® 1059B to newer production lines that utilize their latest flash-spinning technology. The extensive effort is focused on generating data to prove that the Tyvek® produced on the new lines is functionally equivalent to the currently manufactured Tyvek®.
The U.S. FDA has affirmed functional equivalence for Transition Tyvek® and has notified the industry of this news.
Click here to read the latest MPTP update from DuPont.
Click here to access the DuPont MPTP website for the latest project updates.
Contact Us for our Tyvek® Transition Qualification Summary documents.
